Van Norman Gail A
Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, Washington, USA.
JACC Basic Transl Sci. 2023 Feb 27;8(2):224-233. doi: 10.1016/j.jacbts.2022.12.011. eCollection 2023 Feb.
Once medical drugs and devices are approved for marketing by the FDA they can legally be used for purposes and in ways other than the ones for which they have been tested and approved. However, it is illegal for manufacturers to advertise or promote such unapproved uses of the drugs and devices. Part 1 of this review focuses on off-label use of FDA-approved therapies. Part 2 addresses illegal off-label marketing of drugs and devices. While off-label use can be beneficial to patients, unless carefully undertaken off label use may undermine the important safety mission of the FDA, can expose patients to elevated risks without proven benefits (or possibly no benefit), and can reduce motivation of companies to study the safety and risks of off-label use of therapies. These problems are further amplified when off-label use occurs among very vulnerable patient populations such as the elderly, patients with mental health disorders, pregnant women and pediatric patients. This review considers ethical issues in off-label use, as well as important steps for physicians considering an off-label prescription of a drug or device.
一旦药品和医疗器械获得美国食品药品监督管理局(FDA)批准上市,它们就可以合法地用于未经测试和批准的目的及方式。然而,制造商宣传或推广药品和器械的此类未批准用途是违法的。本综述的第一部分重点关注FDA批准疗法的非标签使用。第二部分讨论药品和器械的非法非标签营销。虽然非标签使用可能对患者有益,但除非谨慎进行,否则非标签使用可能会破坏FDA的重要安全使命,使患者面临无已证实益处(或可能无益处)的更高风险,还会降低公司研究疗法非标签使用的安全性和风险的积极性。当在老年人、患有精神健康障碍的患者、孕妇和儿科患者等非常脆弱的患者群体中发生非标签使用时,这些问题会进一步加剧。本综述考虑了非标签使用中的伦理问题,以及医生考虑开具药品或器械非标签处方时的重要步骤。